Abstract 1923
Background
OUTBACK is testing the addition of 4 cycles of adjuvant carboplatin/paclitaxel chemotherapy (chemo) after definitive chemoradiation in locally advanced cervix cancer. We aimed to determine characteristics associated with not starting randomly assigned adjuvant chemo.
Methods
We assessed associations between not starting assigned adjuvant chemo and baseline characteristics of: age; race; country; smoking status; ECOG; BMI; FIGO stage; node involvement; and participants’ self-rated physical, role, emotional, cognitive, social functional status, and financial difficulties (by EORTC QLQ-C30). We also assessed for associations with completion of chemoradiation and grade 3-4 toxicities during chemoradiation. Odds ratios (OR), p-values, and 95% confidence intervals (CI) were calculated with univariable and multivariable logistic regression analyses.
Results
Adjuvant chemo was not started in 105 of 463 (23%) women randomly assigned to receive it. Predictors of not starting adjuvant chemo with a p-value of < 0.05 in univariable analyses, and their effects in multivariable analysis are shown in the table. The odds of not starting chemo were approximately doubled in non-Caucasian women, and those aged >/= 60, even after accounting for other factors.
Conclusions
Adjuvant chemo was less likely to be started in non-Caucasian women, those aged >/= 60, and those with poor self-rated physical function. Further research is required to understand the causes, implications, and methods for mitigating these disparities.
Clinical trial identification
ACTRN12610000732088.
Editorial acknowledgement
Legal entity responsible for the study
University of Sydney.
Funding
National Health and Medical Research Council. In addition, Hospira provided paclitaxel treatment for Australian and New Zealand patients in the study.
Disclosure
L. Mileshkin: Research grant / Funding (self), Provided supply of Paclitaxel for trial patients in Australia and New Zealand: Hospira; Travel / Accommodation / Expenses: Beigene; Travel / Accommodation / Expenses: Roche. K.N. Moore: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Clovis; Advisory / Consultancy, Research grant / Funding (institution): Immunogen; Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy: Aravive; Advisory / Consultancy, Research grant / Funding (institution): OncoMed; Advisory / Consultancy: Samumed; Advisory / Consultancy: Eisai; Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy: Cue; Research grant / Funding (self): Lilly; Research grant / Funding (self): PTC Therapeutics; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Agenus. K. Sjoquist: Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Servier; Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Ipsen; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Astellas; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Bionomics; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Tilray. W. Small: Honoraria (self), Travel / Accommodation / Expenses: Zeiss; Advisory / Consultancy: Merck. S. Thompson: Honoraria (self): Mevion Medical Systems. W. Huh: Honoraria (self): Antiva; Advisory / Consultancy: Inovio. P.A. Disilvestro: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): Immunogen; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Syros; Research grant / Funding (institution): Janssen. D. Rischin: Advisory / Consultancy, Research grant / Funding (institution), Uncompensated: MSD; Advisory / Consultancy, Research grant / Funding (institution), Uncompensated: Regeneron; Advisory / Consultancy, Research grant / Funding (institution), Uncompensated: GSK; Advisory / Consultancy, Research grant / Funding (institution), Uncompensated: BMS; Research grant / Funding (institution): Roche. M.R. Stockler: Research grant / Funding (institution): Astellas; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Bionomics; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Tilray. B.J. Monk: Advisory / Consultancy: AbbVie; Advisory / Consultancy: Advaxis; Advisory / Consultancy: Agenus; Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: ChemoCare; Advisory / Consultancy: ChemoID; Honoraria (self), Advisory / Consultancy: Clovis; Advisory / Consultancy: Conjupro; Advisory / Consultancy: Esaias; Advisory / Consultancy: Geistlich; Advisory / Consultancy: Genmab; Advisory / Consultancy: Immunogen; Advisory / Consultancy: Immunomedics; Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy: Janssen/Johnson & Johnson; Advisory / Consultancy: Merck; Advisory / Consultancy: Myriad; Honoraria (self), Advisory / Consultancy: Roche/Genentech; Honoraria (self), Advisory / Consultancy: Tesaro. All other authors have declared no conflicts of interest.Table: 1052P
Characteristic | Value | Adjuvant chemo not started/ assigned: N (%) | Univariable OR (95% CI) | Univariable p-value | Multivariable OR (95% CI) | Multivariable p-value |
---|---|---|---|---|---|---|
Age | >/= 60 < 60 | 24/70 (34%) 81 / 393 (21%) | 2.01 (1.2-3.5) | 0.01 | 2.30 (1.10-4.81) | 0.026 |
Race | Other White/Caucasian | 43/127 (34%) 62/336 (18%) | 2.26 (1.4–3.6) | 0.0005 | 2.11 (1.13-3.96) | 0.019 |
Nodes involved | Yes No/unknown | 42/225 (19%) 63/238 (26%) | 0.64 (0.4–0.99) | 0.046 | 0.75 (0.42-1.35) | 0.34 |
QLQ-C30 Physical Function | Worst 33.37% Best 66.67% | 5/11 (45%) 59/310 (19%) | 3.55 (1.05–12.0) | 0.04 | 3.66 (1.03-13) | 0.045 |
Chemoradiation | Not completed Completed | 46/114 (40%) 59/349 (17%) | 3.33 (2.01–5.3) | <0.0001 | 3.21 (1.75-5.88) | 0.0002 |
Resources from the same session
1571 - Thyroid Lobectomy versus Total Thyroidectomy among Early-Stage Papillary Thyroid Carcinoma Patient
Presenter: Sara Ahmed
Session: Poster Display session 2
Resources:
Abstract
5051 - Classification of thyroid nodule using DNA methylation profiling on tissue and circulating tumor DNA
Presenter: Shubin Hong
Session: Poster Display session 2
Resources:
Abstract
4155 - Durvalumab plus Tremelimumab for the Treatment of Patients (pts) with Refractory and Progressive Advanced Thyroid Carcinoma. A Phase II Multicohort Trial (DUTHY / GETNE T1812)
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract